QLUPOD AG: Qlupod signs distribution agreement with Adria Prime DOO in Serbia

Herisau (pta023/06.10.2025/16:35 UTC+2)

Herisau, Switzerland – Qlupod AG, October 6, 2025 (www.qlupod.com)

Strategic partnership expands Qlupod's presence in Southeastern Europe and enables

approval with glucose monitoring function in Serbia.

The Swiss medtech company Qlupod AG announces the signing of a distribution

agreement with Serbian company Adria Prime DOO. Through this partnership, the

distribution of QluPod in the Balkan region will be significantly expanded and the

company's market position in Southeastern Europe further strengthened.

A key element of the cooperation is the simultaneous initiation of the registration

process for QluPod as a medical device in Serbia. The approval is planned to cover all six

vital parameters, including the glucose monitoring function. This extended functionality

is currently not available in the European Union and will enable users in Serbia to benefit

from an even broader application of QluPod.

"With Adria Prime DOO, we have a strong partner at our side to position QluPod in an

important growth region," says Nikola Trajanov, Interim CEO of Qlupod AG. "In

particular, the ongoing registration including all vital parameters with glucose monitoring

represents a significant step forward for us and for our customers in Serbia".

In addition to the QluPod, the company sees significant potential for the QluDoc App in

the region. Once the full version becomes available, Qlupod will expand the rollout

across the entire Balkan region and firmly establish the app there.

The cooperation with Adria Prime DOO marks another milestone in Qlupod's international

expansion strategy. The company continues to pursue its vision of establishing QluPod

as an innovative all-in-one solution for mobile health monitoring worldwide.

About Qlupod:

Qlupod AG is a start-up company in the field of telemedicine and develops innovative

solutions to make patient care efficient and cost-effective. With the QluPod device and

the associated software, the company is endeavouring to shape the future of healthcare.

The offering is aimed at hospitals, care facilities, medical professionals and private

individuals who want to monitor their health independently.

For more information about Qlupod AG and our products, please visit our website at

www.qlupod.com.

Disclaimer:

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Insofar as this document contains forward-looking statements, these do not represent

facts and are characterised by the words "expect", "believe", "estimate", "intend", "aim",

"assume" and similar expressions. These statements express the intentions, opinions or

current expectations and assumptions of Qlupod AG and are based on current plans,

estimates and forecasts which Qlupod AG has made to the best of its knowledge, but do

not claim to be correct in the future. Forward-looking statements are subject to risks and

uncertainties that are difficult to predict and are generally beyond the control of Qlupod

AG. It should be noted that actual events or developments may differ materially from

the events and developments expressed or implied by such forward-looking statements.

(end)

Emitter:	QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland
Contact Person:	Nikola Trajanov
Phone:	+41 71 510 05 45
E-Mail:	ir@qlupod.com
Website:	qlupod.eu
ISIN(s):	CH1222316429 (Share)
Stock Exchange(s):	-
Other Stock Exchanges:	Regelmaessige Kursfeststellung Schweiz